Trial Code
Ages
Location
Gender
Ethnicity
Payment
Nicotine Restrictions
Summary
- We are conducting a clinical trial for a new investigational drug that could be used to treat people with heart failure. The drug is considered ‘investigational’ as it is not yet approved by any public health agency for any kind of treatment.
- We are recruiting male participants and female participants of non-childbearing potential with heart failure aged between 40 and 75.
- The clinical trial will involve having multiple injections under the skin in your abdomen.
- The trial will help us determine how safe and tolerable the drug is, how long the drug stays in the body, and how the drug affects the body.
- You will be reimbursed for your time if you take part in this clinical trial.
If you are interested in participating in the trial:
- You will need to attend a screening appointment (Visit 1 or V1) at the trial unit so we can check if you are suitable to take part in the trial. At this appointment, we will perform several assessments, including but not limited to taking blood, checking your heart function, and carrying out a physical examination.
- If results from your screening appointment show you are suitable for the trial, you will be invited to take part.
- The trial will involve:
- Visit 2 (V2): An in-clinic stay of 6 days / 5 nights where you will receive the trial drug via an injection under the skin in your abdomen (subcutaneous injection) and be closely monitored for safety. There will also be a number of assessments (like those at screening) conducted to check how safe and tolerable the drug is, how long the drug remains in your body and how the drug affects your body.
- Visits 3, 4 and 5 (V3, V4 and V5): Each visit is an in-clinic stay of 4 days / 3 nights. Similar to V2, you will receive the trial drug, undergo safety monitoring and assessments.
- Visits 6, 7, 8, 9 and 10 (V6, V7, V8, V9 and V10): After your in-clinic stays, you will be required to return for further 5 follow-up appointments.
- This means the whole process takes approximately 13 weeks from your screening visit through to your final visit. In total, you will have to attend the trial unit on approximately 10 occasions.
Who can take part?
We will check your suitability for the clinical trial using the following criteria:-
- You are a male or a female of non-childbearing potential aged between 40 and 75 (inclusive) at time of screening.
- You have a body mass index (BMI) between 18.5 and < 40 kg/m2.
- You have been diagnosed with heart failure, or you are experiencing symptoms or need medications that suggest you may have heart failure.
- You do not have a known history of serious allergic reactions.
- You are willing and able to comply with the trial visits and trial-related assessments.
A full list of do’s and don’ts will be given to you by a member of our recruitment team if you are interested.
Payment
In recognition of the time involved in taking part in the trial, you will receive £4,000 (£2,666.67 clinical trial payment and £1,333.33 compliance bonus) on successful completion of the clinical trial, provided you comply fully with all the clinical trial requirements. This amount is based on the anticipated clinical trial plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.
Dates
Call us on 020 7042 58002 for information regarding dates.
Approval
Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this study.
This study is sponsored and funded by Novo Nordisk.
Ref: C24020_Jun-2025 (email_website_advert text)
